The Canadian market has a structural quirk that every long-term investor eventually runs into: the S&P/TSX Composite is heavily concentrated in a small number of sectors. As of July 2026, financials alone represent roughly 31% of the index, energy adds another significant share, and combined with materials, these three sectors make up somewhere between 60% and 65% of the entire TSX Composite.
That concentration has genuine advantages — Canadian banks and energy producers have delivered real strength through 2026, and the TSX has repeatedly touched record highs on the back of energy and materials strength. But it also means the TSX offers very little direct exposure to some of the most powerful growth trends currently reshaping the global economy: artificial intelligence, cloud computing, and next-generation healthcare.
This is why many Canadian investors choose to complement their domestic holdings with global growth stocks.
In this article, we apply an objective screening methodology to a broad universe of growth companies, fact-check the results against each company’s most recent quarterly reporting as of August 2026, and present seven companies whose current combination of growth, quality, competitive advantage, and valuation stands out. This is not a simple refresh of last year’s picks — every company here was re-evaluated against current evidence, and the list changed as a result.
This article is for educational purposes only. It does not constitute personalized financial or tax advice, and nothing here should be read as a recommendation to buy or sell any specific security.
The Criteria Used to Select These Companies
Before naming any company, it’s worth being explicit about what “growth stock” actually means in this analysis, because the term gets used loosely.
Revenue growth. We looked for companies posting strong current revenue growth, generally well above the 15-20% range that would be considered strong for a large, established business.
Profitability and free cash flow.
Growth on its own isn’t enough — it needs to increasingly translate into real earnings and cash generation, not just top-line expansion funded by ever-larger spending.
Competitive advantage.
We favored companies with durable moats: market leadership, high switching costs, network effects, proprietary technology, or manufacturing scale that would be extremely difficult for a competitor to replicate.
A structural growth catalyst.
The company should be riding a trend with multi-year staying power, not a temporary spike in demand.
Balance sheet quality. Strong cash positions and manageable debt matter more when a company is also making enormous capital commitments, as several names on this list currently are.
Valuation.
This is the criterion most often skipped in “best stocks” lists, and it shouldn’t be. A fantastic company can still be a mediocre investment if its stock price already assumes years of flawless execution. Great company does not automatically mean great stock at any price.
Risk/reward.
Finally, we weighed what could go wrong against what’s already priced in.
We did not select any company simply because its stock price had performed well recently — several genuinely strong businesses were left off this list, and a few names investors might expect to see (certain high-flying AI software names, for instance) were deliberately excluded because current valuations appear to price in a level of perfection that leaves little room for disappointment.
1. Amazon (AMZN) — The Cloud Story That Convinced the Market
Amazon delivered the most complete quarter of any mega-cap this earnings season, and the market’s reaction reflected that clearly.
In its second quarter of 2026, Amazon’s total revenue crossed $200 billion for the first time in a single quarter, up 20% year-over-year. The more important number sits inside that total: AWS revenue accelerated to 37% year-over-year growth — its fifth consecutive quarter of acceleration and its fastest pace since 2021 — while AWS operating margin expanded to 39.4%. Advertising revenue grew 26% to $19.8 billion, continuing to build out what has quietly become one of the most profitable parts of Amazon’s business. Operating income rose 43% to $27.5 billion.
Amazon also raised its 2026 capital expenditure guidance to roughly $220 billion, up from $200 billion, driven largely by AI and cloud infrastructure investment. What makes this notable is the contrast with how the market treated similar announcements elsewhere. When Alphabet raised its capex guidance the same reporting season, its stock fell. When Meta did the same, its stock fell 8-10%. When Amazon raised its capex guidance by an even larger amount, its stock rose about 9.5% and pushed the company’s market capitalization past $3 trillion for the first time. The distinguishing factor was credibility: AWS’s growth rate accelerated rather than decelerated even as spending rose, giving investors a clear, current link between the capital being deployed and the revenue being generated.
Valuation and risk. Amazon’s mix of cloud, retail, and advertising gives it a more diversified earnings base than pure AI-infrastructure plays, and the market’s reaction to this quarter suggests current spending is, for now, viewed as well-justified. The main risk is straightforward: if AWS growth were to decelerate from here while the elevated capex pace continues, the market’s current confidence could reverse quickly, as it has for peers.
2. Taiwan Semiconductor (TSM) — The Foundry Behind Everyone Else’s Chips
If Nvidia designs the chips and Broadcom customizes them, TSMC is the company that actually manufactures nearly all of them. Without TSMC’s foundries, Nvidia, Apple, AMD, and Broadcom would have no way to physically produce their most advanced products.
TSMC’s second-quarter 2026 results showed revenue of $40.2 billion, up 33.7% year-over-year in U.S. dollar terms and up 36.0% in local currency, with the increase driven overwhelmingly by demand for leading-edge process nodes. Gross margin came in at 67.7%, operating margin at 60.3%, and net margin at an extraordinary 55.6% — figures that reflect genuine pricing power in a market where TSMC effectively sets the terms. Advanced technologies (7-nanometer and below) now account for 77% of wafer revenue, and 2-nanometer production is ramping, with management guiding full-year 2026 revenue growth to slightly above 40% in U.S. dollar terms.
Valuation and risk. TSMC has historically traded at a lower price-to-earnings multiple than many U.S. software and AI companies despite comparable or superior growth, a gap the original version of this article also highlighted and one that has persisted into 2026. The most significant risks are geopolitical — TSMC’s manufacturing base remains concentrated in Taiwan — along with customer concentration, since a small number of large clients account for a substantial share of revenue.
3. Nvidia (NVDA) — Still the AI Leader, Now at a More Reasonable Price
Nvidia remains the most dominant single company in AI computing, but 2026 has been an unusual year for the stock: the business kept growing explosively while the share price lagged behind that growth.
Nvidia’s fiscal Q1 2027 results (reported in May) showed revenue of $81.6 billion, up 85% year-over-year, with the data center segment alone generating the vast majority of that total. The company guided fiscal Q2 revenue to approximately $91 billion. Yet despite this growth, NVDA shares were up only around 17.7% year-to-date as of early August 2026, meaningfully lagging smaller AI-adjacent semiconductor names like AMD and Micron over the same period. The result is a forward price-to-earnings ratio that has compressed to roughly 22-24x — near a decade-low valuation for the company, and, according to some analysts, arguably the most interesting risk/reward setup in the group purely on a valuation basis.
Valuation and risk. Nvidia’s AI accelerator market share, currently around 80%, is widely expected to moderate toward the mid-70s as hyperscalers develop more of their own custom silicon (a trend that directly benefits Broadcom, discussed below) and as AMD’s competing chips gain traction. That competitive erosion is a real, structural risk worth taking seriously — but the current valuation appears to already reflect meaningfully more caution than the growth numbers alone would suggest.
4. Broadcom (AVGO) — The Custom Silicon Powering the Rest of the AI Buildout
Broadcom is a new addition to this list, and the case for including it is straightforward: its most recent quarter showed some of the cleanest AI-driven growth of any company covered here, with an unusually high degree of revenue visibility.
In its fiscal second quarter of 2026, Broadcom reported revenue of $22.2 billion, up 48% year-over-year, with AI semiconductor revenue reaching $10.8 billion, up 143%. Management guided AI semiconductor revenue to grow over 200% year-over-year in the following quarter and reaffirmed a full-year AI semiconductor target of $56 billion, implying roughly 180% growth for the segment in fiscal 2026, with a 2027 target exceeding $100 billion. Free cash flow reached $10.3 billion for the quarter, or 46% of revenue — one of the strongest free cash flow margins of any large technology company.
What differentiates Broadcom from a pure demand story is the structure behind that growth: much of its AI semiconductor revenue is tied to long-term, multi-generation agreements with a small number of hyperscale customers, including Google, Meta, OpenAI, and Anthropic, who rely on Broadcom to help design and manufacture custom AI accelerators (often called ASICs) tailored to their own workloads, along with the networking silicon that connects large clusters of chips together. This gives Broadcom exposure to the same AI infrastructure buildout as Nvidia, but through a different, complementary part of the stack.
Valuation and risk. Broadcom trades at a premium multiple that reflects its growth profile, and investors should treat that premium as a real cost, not a technicality. The most significant risk is customer concentration: Broadcom has described its AI growth as substantially dependent on six core hyperscale customers, and any pullback or renegotiation from even one of them could have an outsized impact on results.
5. Microsoft (MSFT) — A Quality Compounder That Got Cheaper
Microsoft remains the most diversified way to gain exposure to enterprise AI adoption, and 2026 delivered an unusual opportunity: a genuine valuation reset in the middle of continued strong growth.
Microsoft’s fiscal Q4 2026 results (reported July 29, covering the quarter ended June 30) showed revenue of $90.0 billion, up 18% year-over-year, with Azure and other cloud services growing 43% — reaccelerating from the prior quarter and pushing full-year Azure revenue past $100 billion for the first time. Microsoft 365 Copilot surpassed 30 million paid seats, up from 20 million in the prior quarter. Notably, Microsoft shares had actually fallen roughly 19% year-to-date heading into this report, weighed down by anxiety over AI infrastructure spending, before jumping nearly 9% on the earnings release and adding roughly $260 billion in market value in a single session.
Valuation and risk. That earlier pullback means Microsoft is not trading at the stretched multiples some mega-caps carried earlier in the AI cycle, even after its post-earnings rally. The company’s main risk is the sheer scale of its capital commitments — guidance points to fiscal 2027 capital expenditures and finance leases of roughly $255-260 billion, a substantial increase that will need to keep converting into Azure growth for the market to remain comfortable with the spending pace.
6. Alphabet (GOOGL) — The Fastest Cloud Growth, With a Live Valuation Debate
Alphabet posted the single fastest cloud growth rate of any hyperscaler this earnings season, yet its stock sold off on the news — a genuine tension worth understanding rather than glossing over.
In its second quarter of 2026, Alphabet’s revenue rose 24% year-over-year to $119.8 billion, powered by an 82% surge in Google Cloud revenue to $24.8 billion, with cloud operating margin more than tripling to 35.6%. Search revenue grew 17% to $63.3 billion. Operating income rose 30% to $40.8 billion. However, capital expenditures hit a record $44.9 billion for the quarter, pushing free cash flow into negative territory at -$5.9 billion, and management raised its full-year capex guidance to $195-205 billion, up from $180-190 billion previously, while warning that 2027 spending would increase significantly further. Shares fell in after-hours trading despite the revenue and cloud beat.
Valuation and risk. Alphabet’s core search business remains an extraordinarily profitable cash engine, and its cloud acceleration is arguably the most impressive of any company on this list on a growth-rate basis. But the negative free cash flow this quarter, combined with an unusually large forward capex commitment, means the investment thesis for Alphabet currently depends more than most on continued conversion of that spending into durable, high-margin cloud revenue over the next several quarters — a bet the market is clearly still debating in real time.
7. Eli Lilly (LLY) — Healthcare Growth That Doesn’t Depend on the AI Cycle
Eli Lilly’s inclusion on this list serves a different purpose than the six technology names above: it offers a structural growth catalyst that has nothing to do with AI infrastructure spending, which is valuable diversification within an otherwise concentrated list.
Eli Lilly’s second-quarter 2026 results (reported August 5) showed revenue of $23.0 billion, up 48% year-over-year, driven by continued demand for its GLP-1 medicines Mounjaro (+91% to $9.9 billion) and Zepbound (+44% to $4.9 billion). Gross margin expanded to 86.3%. The company raised its full-year 2026 revenue guidance to $85-87 billion, up from a prior $82-85 billion range, and raised non-GAAP EPS guidance as well. The quarter also marked the first to include sales of Foundayo, Lilly’s newly approved obesity pill.
Valuation and risk. Lilly’s growth rate is genuinely comparable to the fastest-growing technology names on this list, which is remarkable for a company of its size and sector. That said, the stock has historically carried a rich valuation relative to traditional pharmaceutical peers, and the company faces real, sector-specific risks: pricing pressure (realized prices for Mounjaro and Zepbound have been declining even as volume grows), rising GLP-1 competition internationally, and ongoing litigation with the FDA over the regulatory pathway for an experimental medicine, retatrutide, which has pushed back its expected filing timeline.
A Note on Concentration Risk
Five of the seven companies on this list — Nvidia, Microsoft, Amazon, Alphabet, and Broadcom — are directly tied to the same underlying trend: the buildout of AI infrastructure. That is a deliberate outcome of the screening methodology, not an oversight. The strongest growth, quality, and revenue visibility currently available in global large-cap equities happens to be concentrated in this trend, and forcing artificial sector diversification into the list would have meant including weaker candidates simply to check a box.
That said, investors should treat this concentration as a real portfolio consideration, not a footnote. If AI infrastructure spending were to slow meaningfully, or if the revenue these companies expect from that spending failed to materialize as quickly as guided, several of these positions could be affected simultaneously, in the same direction, at the same time. This is precisely why Eli Lilly’s inclusion matters beyond its own merits — it represents a structurally different risk driver within the list. Investors relying heavily on this list should still think carefully about their overall portfolio concentration, both within AI-related names and relative to their broader holdings, including Canadian equities.
How to Invest in These Companies (For Canadian Investors)
Canadian investors have two broad paths to gaining exposure to companies like these: buying individual shares directly, or gaining diversified exposure through an ETF.
Buying the Stocks Directly
All seven companies above trade on U.S. exchanges and can be purchased through any Canadian brokerage in a TFSA, RRSP, or non-registered account. Buying individual stocks offers concentrated exposure to the specific companies an investor believes in most, but it also means company-specific risk is not diversified away — a disappointing quarter from any single name can meaningfully affect a concentrated position in a way it would not affect a diversified fund.
ETF Alternatives
For investors who want exposure to this theme without picking individual winners, several Canadian-listed ETFs provide diversified access.
VFV – Vanguard S&P 500 Index ETF.
VFV tracks the S&P 500 and includes meaningful weightings in most of the companies discussed above (Nvidia, Microsoft, Amazon, Alphabet, Broadcom, and Eli Lilly are all S&P 500 constituents), alongside hundreds of other large U.S. companies. It offers very low fees and broad diversification, though its technology weighting is naturally lower than a pure growth or Nasdaq-focused fund, since it also includes financials, healthcare, industrials, and other sectors in proportion to their S&P 500 weight.
QQC – Invesco NASDAQ-100 Index ETF
(CAD-hedged or unhedged, depending on share class).
QQC tracks the Nasdaq-100, which is far more concentrated in technology and growth companies than the S&P 500, and includes Nvidia, Microsoft, Amazon, Alphabet, and Broadcom among its largest holdings. For investors who specifically want to maximize their weighting toward large-cap technology and AI-related growth, QQC generally offers more concentrated exposure than VFV. Eli Lilly, as a healthcare company, is not included in the Nasdaq-100.
The trade-off between individual stocks and ETFs is worth stating plainly: individual stocks offer the potential for outsized returns if you correctly identify the strongest performers, but carry meaningfully higher company-specific risk. ETFs sacrifice some of that upside concentration in exchange for instant diversification across dozens or hundreds of companies, which reduces the damage any single disappointing quarter can do to a portfolio. Neither approach is inherently better — the right choice depends on an investor’s risk tolerance, time available for research, and conviction level in specific companies versus a broader trend.
Tax Considerations for Canadian Investors
The account you hold U.S. stocks in has a real impact on your after-tax returns. The following is general educational information based on current Canada-U.S. tax treaty provisions and is not personalized tax advice — rules can be nuanced depending on individual circumstances, and investors should consult a tax professional for guidance specific to their situation.
U.S. Stocks in an RRSP
Under the Canada-U.S. tax treaty, dividends paid by U.S. companies held within an RRSP (or RRIF) are exempt from the 15% U.S. non-resident withholding tax that would otherwise apply. This exemption is specific to retirement accounts recognized under the treaty and does not extend to a TFSA. For this reason, an RRSP is often considered a more tax-efficient place to hold U.S. dividend-paying stocks specifically.
U.S. Stocks in a TFSA
The TFSA does not benefit from the same treaty exemption, so the 15% U.S. withholding tax still applies to dividends paid on U.S. stocks held in a TFSA. However, the TFSA’s core advantage remains fully intact: all capital gains realized within a TFSA are completely tax-free in Canada, with no reporting required. For growth companies that pay little or no dividend — a description that applies to several names on this list, including Amazon and Alphabet — the drag from U.S. withholding tax is minimal, since there’s little or no dividend income to withhold tax on in the first place. This makes the TFSA a reasonable venue for growth-oriented, low-dividend positions.
Non-Registered Accounts
In a non-registered account, the 15% U.S. withholding tax applies to dividends, but Canadian investors can generally claim a foreign tax credit on their Canadian tax return to avoid double taxation, since the dividend income is also taxable in Canada. Capital gains in a non-registered account are taxable in Canada as well, though only 50% of a capital gain is currently included in taxable income under Canadian tax rules.
Investing in Growth Stocks in a Volatile Market
2026 has been a reminder that even exceptional companies can see sharp, fast stock price swings. Several of the companies on this list — Meta, Alphabet, and Microsoft among the ones discussed here — saw single-day stock moves of 8% or more, in both directions, purely on the market’s interpretation of a single earnings report. This kind of volatility is a normal feature of high-growth investing, not a sign that something has gone wrong.
A gradual entry approach, spreading purchases over weeks or months rather than committing capital all at once, can reduce the risk of poor timing on any single position. Some investors also look to use sharp pullbacks in high-quality names as opportunities to add to positions at more attractive valuations, though this requires genuine conviction in the underlying business rather than simply assuming any decline will be temporary.
Above all, a long-term perspective matters more for this category of investment than almost any other. The structural trends discussed throughout this article — AI infrastructure buildout, cloud computing adoption, and the GLP-1-driven transformation of obesity treatment — are multi-year stories, not single-quarter events, and the companies best positioned to benefit from them are likely to see their fair share of volatile quarters along the way.
Conclusion
Growth stocks remain one of the more powerful tools available for building long-term wealth, and 2026 has reinforced why global diversification matters for Canadian investors specifically: the TSX’s heavy concentration in financials, energy, and materials means genuine exposure to AI infrastructure, cloud computing, and next-generation healthcare has to be sought out elsewhere.
Amazon, Taiwan Semiconductor, Nvidia, Broadcom, Microsoft, Alphabet, and Eli Lilly each offer a different combination of growth, quality, and risk as of August 2026 — and, notably, this list looks different from where it stood at the start of the year, because the evidence changed. Investors researching this space should keep watching the same signals highlighted throughout this article for each company: whether revenue growth is translating into real cash flow, whether capital spending is converting into visible, contracted revenue rather than speculative buildout, and whether current valuations still leave reasonable room for error.
As always, a diversified approach — one that considers position sizing, account type, and overall portfolio concentration alongside individual stock selection — remains the more prudent path than concentrating heavily in any single name or theme, however compelling the growth story looks today.
